RxDoctor Payments Data

Maung Maung, MD

Internal Medicine · Flushing, NYNPI 1548219041

Payments from drug & device makers

$5,043in general payments, 2019–2025

Across 194 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Amarin Pharma, Inc.$829
  • AbbVie$599
  • AstraZeneca$495
  • Amgen$463
  • Lilly USA, LLC$365
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,032100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,043 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$42,484
Medicare patients
80
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl978$451,739
JanuviaSitagliptin Phosphate146$120,030
Diclofenac Epolamine143$90,017
EliquisApixaban74$60,634
RestasisCyclosporine64$44,478
ProliaDenosumab19$32,770
ArexvyRsvpref3 Antigen/As01e/Pf123$32,156
JardianceEmpagliflozin29$32,107
XareltoRivaroxaban43$30,324
VemlidyTenofovir Alafenamide19$26,060
FarxigaDapagliflozin Propanediol20$25,816
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$24,400
TradjentaLinagliptin22$17,507
Lactulose14$17,419
Icosapent Ethyl96$16,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$39$120,030146 claims
GSKArexvy, Anoro Ellipta, Shingrix$121$68,360238 claims
AbbVieRestasis, Linzess, Synthroid$599$62,188174 claims
PfizerEliquis$19$60,63474 claims
Boehringer IngelheimJardiance, Tradjenta$18$49,61451 claims
AmgenProlia$463$32,77019 claims
Johnson & JohnsonXarelto$111$30,32443 claims
GileadVemlidy$1,111$26,06019 claims
AstraZenecaFarxiga$495$25,81620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →